Novo Nordisk | NVO - Operating Expenses


Novo Nordisk reported DKK6.96B in Operating Expenses for its fiscal quarter ending in June of 2026.





Operating Expenses Change Date
ANI Pharmaceuticals USD 562.3M 344.37M Mar/2026
Aurora Cannabis CAD 48.04M 81.94M Mar/2026
Bausch Health Companies USD 2.08B 41M Jun/2026
Bristol-Myers Squibb USD 22.32B 2.25B Jun/2026
Canopy Growth CAD 98.72M 11.51M Mar/2026
Corcept Therapeutics USD 214.85M 343K Jun/2026
Drreddys Laboratories INR 74.33B 1.4B Mar/2026
Eli Lilly USD 10.52B 496M Jun/2026
GlaxoSmithKline GBP 5.8B 468M Jun/2026
Merck USD 15.77B 2.4B Jun/2026
Nektar Therapeutics USD 49.12M 8.22M Mar/2026
Novartis USD 10.2B 912M Jun/2026
Novo Nordisk DKK 44.73B 7.52B Jun/2026
Novo Nordisk DKK 6.96B 30.25B Jun/2026
Pacira USD 180.54M 7.79M Jun/2026
Perrigo USD 290.5M 645.1M Jun/2026
Phibro Animal Health USD 361.83M 29.47M Mar/2026
Prestige Brands USD 206.12M 5.17M Mar/2026
Sanofi EUR 9.92B 607M Jun/2026
Supernus Pharmaceuticals USD 1.03B 45.58M Jun/2026
Zoetis USD 3.23B 1.68B Mar/2026